SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Weiden, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiden, P. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Switching antipsychotics: an updated review with a focus on quetiapine

Peter J. Weiden

Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY, USA, peter.weiden{at}downstate.edu

Atypical antipsychotics offer broader efficacy and improved tolerability compared with conventional agents. Many patients currently treated with conventional antipsychotics continue to experience persistent symptoms or troublesome side effects and may benefit from a change to one of the newer atypical agents. There are also significant differences in the side-effect profiles of the atypicals, such that a switch from one atypical agent to another could offer advantages to many patients. Unfortunately, many clinicians remain uncertain about the switching process and are reluctant to initiate change. The aim of this review is to identify the indications for a switch in antipsychotic therapy with a focus on recent switching data for the atypical antipsychotic, quetiapine. The clinical aspects of quetiapine’s receptor binding characteristics are reviewed including the implications of the low D2 antagonist properties that make quetiapine the treatment of choice when EPS persists with other atypical antipsychotics. Practical guidelines are given for managing the process of changeover, for avoiding pitfalls and for maximizing the chances of a successful switch. For example, when managing the antipsychotic crossover, it is important to consider the psychological effects of switching arising from symptom and side-effect changes. Finally, advice is provided on the assessments necessary when evaluating the success of a change in therapy, together with guidance on the optimal duration of treatment trials.

Key Words: schizophrenia • antipsychotics • partial response • quetiapine • anticholinergic • EPS • switching • withdrawal

References

  • Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis . Am J Psychiatry 156: 1686-1696 [Abstract/Free Full Text]
  • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes . Diabetes Care 27: 596-601 [Free Full Text]
  • Arvanitis L A, Miller B G, the Seroquel Trial 13 Study Group (1997) Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo . Biol Psychiatry 42: 233-246 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • AstraZeneca (2004) Seroquel® (quetiapine fumarate) tablets/US prescribing information. Available at http://www.astrazeneca-us.com/pi/Seroquel.pdf. Accessed 15 June 2004
  • Barnes T R, Braude W M (1985) Akathisia variants and tardive dyskinesia . Arch Gen Psychiatry 42: 874-878 [Abstract/Free Full Text]
  • Beasley Jr C M, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial . Psychopharmacology (Berl) 124: 159-167 [CrossRef][Medline] [Order article via Infotrieve]
  • Bilder R M, Goldman R S, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper T B, Horowitz T L, Lieberman J A (2002) Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder . Am J Psychiatry 159: 1018-1028 [Abstract/Free Full Text]
  • Braff D L, Saccuzzo D P (1982) Effect of antipsychotic medication on speed of information processing in schizophrenic patients . Am J Psychiatry 139: 1127-1130 [Abstract/Free Full Text]
  • Brecher M, Rak I W, Melvin K, Jones A M (2000) The long-term effect of quetiapine (SeroquelTM) monotherapy on weight in patients with schizophrenia . Int J Psychiatry Clin Pract 4: 287-291
  • Burke R E, Kang U J, Jankovic J, Miller L G, Fahn S (1989) Tardive akathisia: an analysis of clinical features and response to open therapeutic trials . Mov Disord 4: 157-175 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Casey D E, Carson W H, Saha A R, Liebeskind A, Ali M W, Jody D, Ingenito G G (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study . Psychopharmacology (Berl) 166: 391-399 [Medline] [Order article via Infotrieve]
  • Covell N H, Jackson C T, Evans A C, Essock S M (2002) Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles . Schizophr Bull 28: 17-29 [Abstract/Free Full Text]
  • Delassus-Guenault N, Jegouzo A, Odou P, Seguret T, Zangerlin H, Vignole E, Robert H (1999) Clozapine-olanzapine: a potentially dangerous switch . A report of two cases. J Clin Pharm Ther 24: 191-195
  • De Nayer A, Windhager E, Irmansyah, Larmo I, Lindenbauer B, Rittmannsberger H, Platz T, Jones A M, Whiteford J L, Altman C A, on behalf of the SPECTRUM Study Group (2003) Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics . Int J Psychiatry Clin Pract 7: 59-66 [CrossRef]
  • Dilsaver S C, Alessi N E (1988) Antipsychotic withdrawal symptoms: phenomenology and pathophysiology . Acta Psychiatr Scand 77: 241-246 [Medline] [Order article via Infotrieve]
  • Dolder C R, Jeste D V (2003) Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients . Biol Psychiatry 53: 1142-1145 [CrossRef][Medline] [Order article via Infotrieve]
  • Drake R E, Cotton P G (1986) Depression, hopelessness and suicide in chronic schizophrenia . Br J Psychiatry 148: 554-559 [Abstract/Free Full Text]
  • Drake R E, Gates C, Cotton P G (1986) Suicide among schizophrenics: a comparison of attempters and completed suicides . Br J Psychiatry 149: 784-787 [Abstract/Free Full Text]
  • Eli Lilly and Company (2003) Olanzapine Prescribing Information. Zyprexa® (olanzapine) tablets. Available at http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed 14 January 2004
  • Emsley R A (1999) Partial response to antipsychotic treatment: the patient with enduring symptoms . J Clin Psychiatry 60(Suppl. 23): 10-13
  • Emsley R A, Raniwalla J, Bailey P J, Jones A M, on behalf of the PRIZE Study Group (2000) A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment . Int Clin Psychopharmacol 15: 121-131 [Web of Science][Medline] [Order article via Infotrieve]
  • Expert consensus panel for optimizing pharmacologic treatment of psychotic disorders (2003) The expert consensus guideline series . Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 64(Suppl. 12): 5-100
  • Gardner D M, Baldessarini R J, Benzo J, Zarate Jr C A, Tohen M (1997) Switching between clozapine and risperidone treatment . Can J Psychiatry 42: 430-431 [Web of Science][Medline] [Order article via Infotrieve]
  • Gefvert O, Lundberg T, Wieselgren I M, Bergstrom M, Langstrom B, Wiesel F, Lindstrom L (2001) D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study . Eur Neuropsychopharmacol 11: 105-110 [CrossRef][Medline] [Order article via Infotrieve]
  • Ghaemi S N, Cherry E L, Katzow J A, Goodwin F K (2000) Does olanzapine have antidepressant properties? A retrospective preliminary study . Bipolar Disord 2: 196-199 [Medline] [Order article via Infotrieve]
  • Gilbert P L, Harris M J, McAdams L A, Jeste D V (1995) Neuroleptic withdrawal in schizophrenic patients . A review of the literature. Arch Gen Psychiatry 52: 173-188
  • Gillain B, Van Peborgh P, De Brueeker G, Peuskens J (2002) Quetiapine clinical use in real-life environment - the SECURE Study . Eur Neuropsychopharmacol 12(Suppl. 3): S263 , abs P.2.021
  • Goldstein J M, Arvanitis L A, Thyrum P T, Yeh C (1998) Safety and tolerability of switching from conventional antipsychotic therapy to SEROQUEL® (quetiapine fumarate) followed by abrupt withdrawal from SEROQUEL . Poster presented at the Institute of Psychiatric Services Annual Meeting, Los Angeles, CA, USA, 2-6 October
  • Goodnick P J, Jerry J M (2002) Aripiprazole: profile on efficacy and safety . Expert Opin Pharmacother 3: 1773-1781 [CrossRef][Medline] [Order article via Infotrieve]
  • Hatzimanolis J, Lykouras L, Markianos M, Oulis P (1998) Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine . Prog Neuropsychopharmacol Biol Psychiatry 22: 1077-1085 [Medline] [Order article via Infotrieve]
  • Hirose S (2003) The causes of underdiagnosing akathisia . Schizophr Bull 29: 547-558 [Abstract/Free Full Text]
  • Hummer M, Fleischhacker W W (1996) Compliance and outcome in patients treated with antipsychotics: the impact of extrapyramidal syndromes . CNS Drugs 5: 13-20
  • Jellinek T, Gardos G, Cole J O (1981) Adverse effects of antiparkinson drug withdrawal . Am J Psychiatry 138: 1567-1571 [Abstract/Free Full Text]
  • Jibson M D, Tandon R (1998) New atypical antipsychotic medications . J Psychiatr Res 32: 215-228 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kane J M (2001) Extrapyramidal side effects are unacceptable . Eur Neuropsychopharmacol 11(Suppl. 4): S397-S403
  • Kane J M, Leucht S, Carpenter D, Docherty J P (2003) Expert consensus guidelines series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentory and summary . J Clin Psychiatry 64 (Suppl 12): 5-19
  • Kasper S, Brecher M, Fitton L, Jones A M (2004) Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia . Int Clin Psychopharmacol 19: 281-289 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kasper S, Müller-Spahn F (2000) Review of quetiapine and its clinical applications in schizophrenia . Expert Opin Pharmacother 1: 783-801 [CrossRef][Medline] [Order article via Infotrieve]
  • Keck Jr P E, Strakowski S M, McElroy S L (2000) The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia . J Clin Psychiatry 61(Suppl. 3): 4-9
  • Keller R, Mongini F (2002) Switch to quetiapine in antipsychotic agent-related hyperprolactinemia . Neurol Sci 23: 233-235 [CrossRef][Medline] [Order article via Infotrieve]
  • Kleinberg D L, Davis J M, de Coster R, Van Baelen B, Brecher M (1999) Prolactin levels and adverse events in patients treated with risperidone . J Clin Psychopharmacol 19: 57-61 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kopala L, Baldwin D, Weiden P, Hellewell J S (1999) Overcoming challenges in the management of schizophrenia . Int J Psychiatry Clin Pract 3: 11-15
  • Kopala L C (1996) Spontaneous and drug-induced movement disorders in schizophrenia . Acta Psychiatr Scand 389 (Suppl.): 12-17
  • Lehman A F, Kreyenbuhl J, Buchanan R W, Dickerson F B, Dixon L B, Goldberg R, Green-Paden L D, Tenhula W N, Boerescu D, Tek C, Sandson N, Steinwachs D M (2004) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendation 2003 . Schizophr Bull 30: 193-217 [Abstract/Free Full Text]
  • Lehman A F, Lieberman J A, Dixon L B, McGlashon T H, Miller A L, Perkins D O, Kreyenbuhl J (2004) Practice guideline for the treatment of patients with schizophrenia, second edition . Am J Psychiatry 161(Suppl 2): 1-56 [Free Full Text]
  • Leslie D L, Rosenheck R A (2002) From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications . Am J Psychiatry 159: 1534-1540 [Abstract/Free Full Text]
  • Lieberman J A, Saltz B L, Johns C A, Pollack S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia . Br J Psychiatry 158: 503-510 [Abstract/Free Full Text]
  • Luchins D J, Klass D, Hanrahan P, Malan R, Harris J (1998) Alteration in the recommended dosing schedule for risperidone . Am J Psychiatry 155: 365-366 [Abstract/Free Full Text]
  • Manos N, Gkiouzepas J (1981) Discontinuing antiparkinson medication in chronic schizophrenics . At what cost to the patient? Acta Psychiatr Scand 63: 28-32
  • Manos N, Gkiouzepas J, Tzotzoras T, Tzanetoglou A (1981) Gradual withdrawal of antiparkinson medication in chronic schizophrenics: Any better than the abrupt? J Nerv Ment Dis 169: 659-661 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Marder S R, Essock S M, Miller A L, Buchanan R W, Casey D E, Davis J Met al. (2004) Physical health monitoring of patients with schizophrenia . Am J Psychiatry 161(8): 1334-1349 [Abstract/Free Full Text]
  • Masand P S, Gupta S, Virk S, Schwartz T, Hameed A, Frank B L, Lockwood K (2003) Effects on weight change of switching from olanzapine to quetiapine . Poster P. 46 presented at the World Psychiatric Association, Vienna, Austria, 19-22 June
  • McEvoy J P, Freter S (1989) The dose-response relationship for memory impairment by anticholinergic drugs . Compr Psychiatry 30: 135-138 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McEvoy J P, McCue M, Spring B, Mohs R C, Lavori P W, Farr R M (1987) Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers . Am J Psychiatry 144: 573-577 [Abstract/Free Full Text]
  • Meltzer H Y (1997) Treatment-resistant schizophrenia - the role of clozapine . Curr Med Res Opin 14: 1-20 [Web of Science][Medline] [Order article via Infotrieve]
  • Meltzer H Y (1999) Outcome in schizophrenia: beyond symptom reduction . J Clin Psychiatry 60(Suppl. 3): 3-7
  • Meltzer H Y, Alphs L, Green A I, Altamura A C, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam M Z, Kane J, Krishnan R, Lindenmayer J P, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) . Arch Gen Psychiatry 60: 82-91 [Abstract/Free Full Text]
  • Miller A L, Hall C S, Buchanan R W, Buckley P J, Chiles J, Conley R R, Crimson M L, Ereshefsky L, Essocle S M, Finnerty M, Marder S R, Miller D, McEvoy J, Rush A J, Saeed S A, Schooler N R, Shan S, Stroup S, Tarin-Godoy B (2004) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update . J Clin Psychiatry 65: 500-508 [Web of Science][Medline] [Order article via Infotrieve]
  • Miller D D (2000) Review and management of clozapine side effects . J Clin Psychiatry 61(Suppl. 8): 14-17
  • Mindham R H, Gaind R, Anstee B H, Rimmer L (1972) Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism . Psychol Med 2: 406-413 [Web of Science][Medline] [Order article via Infotrieve]
  • Minzenberg M J, Poole J H, Benton C, Vinogradov S (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia . Am J Psychiatry 161: 116-124 [Abstract/Free Full Text]
  • Moller H J, Muller H, Borison R L, Schooler N R, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a reevaluation of the North American risperidone study . Eur Arch Psychiatry Clin Neurosci 245: 45-49 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Morrison A P, Bowe S, Larkin W, Nothard S (1999) The psychological impact of psychiatric admission: some preliminary findings . J Nerv Ment Dis 187: 250-253 [Medline] [Order article via Infotrieve]
  • Naheed M, Green B (2001) Focus on clozapine . Curr Med Res Opin 17: 223-229 [Medline] [Order article via Infotrieve]
  • Orlov P, Kasparian G, DiMascio A, Cole J O (1971) Withdrawal of antiparkinson drugs . Arch Gen Psychiatry 25: 410-412 [Abstract/Free Full Text]
  • Owens D G C (1994) Extrapyramidal side effects and tolerability of risperidone: a review . J Clin Psychiatry 55(Suppl. 5): 29-35
  • Park S, Ross-Degnan D, Adams A S, Sabín J, Kanavos P, Soumerai S B (2005) Effect of switching antipsychotic on antiparkinsonian medication use in schizophrenia: a population based study . Br J Psychiatry 187: 137-142 [Abstract/Free Full Text]
  • Perenyi A, Gardos G, Samu I, Kallos M, Cole J O (1983) Changes in extrapyramidal symptoms following anticholinergic drug withdrawal . Clin Neuropharmacol 6: 55-61 [Web of Science][Medline] [Order article via Infotrieve]
  • Peuskens J, on behalf of the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol . Br J Psychiatry 166: 712-726 [Abstract/Free Full Text]
  • Peuskens J, Sienaert P, De Hert M (1998) Sexual dysfunction: the unspoken side effect of antipsychotics . Eur Psychiatry 13 (Suppl. 1): 23S-30S
  • Pickar D, Labarca R, Doran A R, Wolkowitz O M, Roy A, Breier A, Linnoila M, Paul S M (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients . Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 43: 669-676
  • Rak I W (2000) Maintenance of long-term efficacy with quetiapine . Poster presented at the American College of Neuropsychopharmacology Annual Meeting, San Juan, PR, USA, 10-14 December
  • Ranjan R, Meltzer H Y (1996) Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression . Biol Psychiatry 40: 253-258 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rothbard A B, Kuno E, Foley K (2003) Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia . Schizophr Bull 29: 531-540 [Abstract/Free Full Text]
  • Sajatovic M, Mullen J A, Sweitzer D E (2002) Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis . J Clin Psychiatry 63: 1156-1163 [Medline] [Order article via Infotrieve]
  • Schulz S C (2000) New antipsychotic medications: more than old wine and new bottles . Bull Menninger Clin 64: 60-75 [Medline] [Order article via Infotrieve]
  • Sheitman B B, Lieberman J A (1998) The natural history and pathophysiology of treatment resistant schizophrenia . J Psychiatr Res 32: 143-150 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Silver H, Geraisy N (1995) Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients . A Double-blind cross-over study. Br J Psychiatry 166: 241-243
  • Simpson G M, Meyer J M (1996) Dystonia while changing from clozapine to risperidone . J Clin Psychopharmacol 16: 260-261 [Medline] [Order article via Infotrieve]
  • Smith M A, McCoy R N, Hamer J, Brecher M, Goldstein J M (2003) Optimal titration for quetiapine: a pilot study . Poster NR568 presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, USA, 17-22 May
  • Strauss M E, Reynolds K S, Jayaram G, Tune L E (1990) Effects of anti-cholinergic medication on memory in schizophrenia . Schizophr Res 3: 127-129 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sweeney J A, Keilp J G, Haas G L, Hill J, Weiden P J (1991) Relationships between medication treatments and neuropsychological test performance in schizophrenia . Psychiatry Res 37: 297-308 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tandon R, Jibson M D (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia . Psychoneuroendocrinology 28(Suppl. 1): 9-26
  • Tollefson G D, Beasley Jr C M, Tran P V, Street J S, Krueger J A, Tamura R N, Graffeo K A, Thieme M E (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial . Am J Psychiatry 154: 457-465 [Abstract]
  • Tollefson G D, Sanger T M (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine . Am J Psychiatry 154: 466-474 [Abstract]
  • Tollefson G D, Sanger T M, Lu Y, Thieme M E (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol . Arch Gen Psychiatry 55: 250-258 [Abstract/Free Full Text]
  • Tune L E, Strauss M E, Lew M F, Breitlinger E, Coyle J T (1982) Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients . Am J Psychiatry 139: 1460-1462 [Abstract/Free Full Text]
  • Van Putten T, May P R A (1978) Subjective response as a predictor of outcome in pharmacotherapy . The consumer has a point. Arch Gen Psychiatry 35: 477-480
  • Velligan D I, Newcomer J, Pultz J, Csernansky J, Hoff A L, Mahurin R, Miller A L (2002) Does cognitive function improve with quetiapine in comparison to haloperidol? . Schizophr Res 53: 239-248 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Verghese C, DeLeon J, Nair C, Simpson G M (1996) Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics . Biol Psychiatry 39: 135-138 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Weiden P J (1996) How to evaluate for acute medication-induced movement disorders . J Pract Psychiatry Behav Health May: 176-180
  • Weiden P J, Aquila R, Dalheim L, Standard J M (1997) Switching antipsychotic medications . J Clin Psychiatry 58(Suppl. 10): 63-72
  • Weiden P J, Aquila R, Emanuel M, Zygmunt A (1998a) Long-term considerations after switching antipsychotics . J Clin Psychiatry 59 (Suppl. 19): 36-49 [Web of Science][Medline] [Order article via Infotrieve]
  • Weiden P J, Daniel D G, Simpson G, Romano S J (2003a) Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone . J Clin Psychopharmacol 23: 595-600 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Weiden P J, Iqbal N, Mendelowitz A, Tandon R, Zimbroff D L, Ross R (2002) Best clinical practice with ziprasidone: update after one year of experience . Journal of Psychiatric Practice 8: 81-97 [Medline] [Order article via Infotrieve]
  • Weiden P J, Mann J J, Haas G, Mattson M, Frances A (1987) Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study . Am J Psychiatry 144: 1148-1153 [Abstract/Free Full Text]
  • Weiden P J, Miller A L (2001) Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications . J Psychiatr Pract 7: 41-47 [CrossRef][Medline] [Order article via Infotrieve]
  • Weiden P J, Scheifler P W, Diamond R J (1998b) Barriers to the effective use of newer medications: the case of Karen . J Pract Psychiatry Behav Health Jan: 43-49
  • Weiden P J, Schleifler P W, Diamond R J (1998c) My patient is better: Now what? Part I . Managing psychological reactions. J Pract Psychiatry Behav Health May: 175-181
  • Weiden P J, Schleifler P W, Diamond R J (1998d) My patient is better: Now what? Part II . Dealing with interpersonal relationships. J Pract Psychiatry Behav Health Sept: 309-315
  • Weiden P J, Simpson G M, Potkin S G, O’Sullivan R L (2003b) Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia . J Clin Psychiatry 64: 580-588 [Web of Science][Medline] [Order article via Infotrieve]
  • Weiden P, Mackell J (1999) Differing side effect burden with newer antipsychotics . Poster presented at the 39th New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, USA, 1-4 June
  • Wudarsky M, Nicolson R, Hamburger S D, Spechler L, Gochman P, Bedwell J, Lenane M C, Rapoport J L (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics . J Child Adolesc Psychopharmacol 9: 239-245 [Web of Science][Medline] [Order article via Infotrieve]
  • Zhong K X, Sweitzer D, Russo J, Potter L, Mullen J (2003) A comparison of the efficacy and safety of quetiapine and risperidone . Poster P.2.140 presented at the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, 20-24 September

This version was published on January 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 1, 104-118 (2006)
DOI: 10.1177/0269881105056668
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
A. Goudie and J. Cole
Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications
J Psychopharmacol, September 1, 2008; 22(7): 815 - 817.
[PDF]

Home page
 Journal of Pharmacy PracticeHome page
A. C. Singh, A. J. Massey, M. D. Thompson, L. R. Rappa, and M. S. Honeywell
Addressing Nonadherence in the Schizophrenic Population
Journal of Pharmacy Practice, December 1, 2006; 19(6): 361 - 368.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Weiden, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiden, P. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement